The Company believes it can discover a stable of novel MANF-like proteins using its proprietary PhenoGuard platform technology. PhenoGuard was originally developed in the Neurotrophic Factors Group at the National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland.
http://www.biospace.com/News/amarantus-biosci...-of/280919

http://finance.yahoo.com/news/amarantus-biosc...00746.html